AEMD

Aethlon Medical, Inc. - 10-Q Summary (Period Ended Dec 31, 2009)

Business Context and Reporting Period

Aethlon Medical, Inc. is a development-stage medical device company focused on the Hemopurifier(R) platform, designed to remove viruses and toxins from human blood. The company has not generated significant revenue from commercial operations and is seeking FDA approval for clinical trials. This report covers the quarterly period ended December 31, 2009, and the nine-month period ended on that date. The company is classified as a "Smaller Reporting Company" and a "Development Stage Company."

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: For the three months ended Dec 31, 2009, operating expenses decreased by 18% to $715,977 compared to $867,369 in the prior year quarter. This was driven by a $344,490 reduction in payroll and related expenses (primarily due to lower stock-based compensation and staff reductions), partially offset by increases in professional fees and general/administrative costs.
• Other Expenses: Other expenses decreased significantly to $769,901 from $1,477,185 in the prior year quarter. The prior period included a $1,063,344 loss on extinguishment of debt and a $607,908 loss on settlement of accrued interest, neither of which occurred in the current period.
• Interest Expense: Interest expense increased to $692,770 for the quarter (from $363,964) primarily due to a $351,000 accrual of liquidated damages resulting from a lapse in the effectiveness of a registration statement filed with the SEC.
• Liquidity: Cash increased from $6,157 at March 31, 2009, to $48,600 at December 31, 2009, funded by financing activities including the issuance of convertible notes and common stock.

Guidance, Outlook, Risks, and Contingencies

• Going Concern: The company has raised significant doubt about its ability to continue as a going concern due to recurring losses, negative working capital of approximately $4.3 million, and a deficit accumulated during the development stage of over $41.5 million. Additional capital is required to fund operations and product development.
• Debt Defaults: As of December 31, 2009, various promissory and convertible notes totaling $1,207,000 in principal were past due and in default. The company is actively seeking financing to retire these obligations.
• Regulatory Status: The company is in the process of obtaining FDA approval to initiate clinical trials in the U.S. for the Hemopurifier(R). Commercialization is contingent upon successful completion of human efficacy and safety trials.
• Financing Activities: The company raised funds through private placements of convertible notes and common stock. Subsequent to the reporting period (Jan/Feb 2010), the company raised an additional $550,000 in convertible notes.
• Legal Proceedings: A lawsuit regarding unpaid rent at a former headquarters was dismissed in November 2009 after the amounts were paid. No other pending litigation was reported.

Key Facts for Investor Verification

• Cash Runway: Verify the sufficiency of the $48,600 cash balance against the stated minimum monthly operating requirement of $150,000.
• Debt Restructuring: Confirm the status of the $1.2 million in past-due debt and the company's ability to convert or repay these obligations without further dilution or default.
• Registration Statement: Verify the status of the SEC registration statement that lapsed, causing the $351,000 liquidated damages accrual, and whether it has been re-filed effectively.
• Derivative Liabilities: Monitor the $587,627 derivative liability, which fluctuates based on stock price and can significantly impact net income/loss.
• Capital Raising: Assess the success of ongoing capital raising efforts mentioned in subsequent events to determine if the company can sustain operations through the next fiscal year.